Board summary
Key figures
58,760
Registered population
59.0% aged 18–64
21.6%
Aged 65+
ICB 18.8% · England 17.9%
11.1%
Ethnic minority (non-White)
5.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
8,287
Hypertension register
+7.32% in 3 yrs · England +5.60%
446
SMI register
41.7% of Guildford's
543
COPD register
Reviews -1.39% in 3 yrs
Forecast to 2030
10,070
Hypertension patients, 2030
+1,783 on today
67.0%
QRISK ≥20% on statins, 2030
+4.44pp over 3 yrs
6.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy sits below England.
Lipid-lowering therapy covers 57.0% of QRISK ≥ 20% patients (England 63.6%) and 62.3% in CKD (England 70.3%), which may reflect escalation gaps.
Twelve three-year trends trail England's pace.
Across 25 measures from 2023 to 2025, 12 trail England, including COPD reviews (-1.4% vs England +2.8%) and heart failure reviews (-0.7% vs +8.7%).
Blood pressure control and screening exceed England.
Hypertension treatment to target reaches 74.3% (England 70.3%), alongside 76.0% uptake for both cervical (England 66.8%) and breast screening (England 69.9%).
Population, age and ethnicity
Registered patients aged 65+ reach 21.6%, exceeding Guildford, ICB and England benchmarks
Across six member practices totalling 58,760 registered patients, 21.6% (12,681) are aged 65+, higher than Guildford (17.5%), NHS Surrey Heartlands ICB (18.8%) and England (17.9%). Working-age adults (18-64) represent 59.0% and children (0-17) 19.4%. Based on Census usual residents (not registered patients), 88.9% identify as White, above Guildford (86.9%), the ICB (85.3%) and England (81.1%), with an 11.1% ethnic minority population including 5.2% Asian or Asian British. Projected list growth to 2030 is 4.4% (unverified methodology). An older demographic could increase frailty and chronic disease demand across practices.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Guildford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Guildford LA) | 2,163 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 88.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 63.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Guildford LA) | 1,054 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Guildford LA) | 9.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.6 with 0.0% Core20 share across all six practices
Guildford East PCN has an average IMD decile of 8.6, above Guildford (7.9), NHS Surrey Heartlands ICB (7.9) and England (5.5). No registered patients reside in national IMD deciles 1 or 2 (0.0% Core20), against 1.0% in Guildford, 0.8% in NHS Surrey Heartlands ICB and 21.0% in England. Practice deciles range from 6.5 at Villages Medical Ctr to 9.1 at Merrow Park Surgery, with 0.0% Core20 across all six practices. Area-based deprivation indices may overlook household-level need, suggesting the PCN focus on clinical vulnerability and inclusion health.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
446
SMI register
0.75% recorded prevalence
178
Learning disability register
0.30% recorded prevalence
25
Care homes, 858 beds
In the PCN catchment
8.0%
Provide unpaid care
Guildford, Census 2021
Learning disability prevalence is 0.3% (178 patients; Guildford 0.4%, ICB 0.5%, England 0.6%) and severe mental illness is 0.8% (446 patients; England 1.0%), alongside 25 catchment care homes (858 beds). Borough unpaid care (8.0%) and rough sleeping (9) are borough metrics not captured at PCN level. Lower recorded learning disability prevalence may reflect identification differences, which a clinical register audit would test.
Severe mental illness: physical health checks
Recorded SMI checks reach 88.4% for blood pressure (England 83.4%) and 88.4% for BMI (England 82.1%). Over 2023 to 2025, smoking cessation support fell 3.1 pp (England +0.1 pp) to 93.2%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,287
Hypertension register
+7.32%
Register growth, 3 yrs
Guildford +5.63% · England +5.60%
+1.15pp
BP control, under 80
≤140/90 · +3.31pp aged 80+
+1,783
More patients by 2030
Forecast 10,070 (16.07%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.9% (8,287 patients), below England (15.2%) and NHS Surrey Heartlands ICB (14.3%) but above Guildford (12.5%). Across practices, recorded prevalence varies from 11.5% at Austen Road Surgery to 16.4% at Villages Medical Ctr. Blood pressure control is strong: 74.3% of patients are treated to target, exceeding England (70.3%), Guildford (72.2%) and the ICB (71.4%). Prevalence differences do not establish undiagnosed disease, but variation alongside high blood pressure control could reflect case-finding differences that an audit would test.
Lipids and statins
Lipid-lowering therapy rates trail England across high-risk cohorts: 57.0% for QRISK ≥ 20% (England 63.6%), 62.3% for CKD (England 70.3%), and 81.2% for diabetes with CVD history (England 84.4%). Lower treatment rates across these high-risk cohorts suggest prioritising a systematic clinical recall review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 62,216 | £2.20 | £2.24 | £1.86 | £136,875 |
| Cardiovascular (all), 2025 | 85,891 | £6.16 | £4.74 | £3.33 | £529,089 |
For lipid-regulating drugs in 2026, the PCN prescribed 62,216 items at £2.20 per item (England £1.86, Guildford £2.15, NHS Surrey Heartlands ICB £2.24), spending £21,153 more than at England's unit cost. Unit cost reflects prescribing choices and formulary mix rather than efficiency, which a local prescribing review would examine.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.38%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.37%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 5.9% (3,360 patients; England 6.6%), and COPD prevalence is 0.9% (543 patients; England 1.9%). While annual reviews exceed national rates—reaching 70.4% in asthma (England 65.7%) and 80.7% in COPD (England 76.4%)—three-year trajectories lag, with COPD reviews falling 1.4% (England +2.8%). An estimated 995 asthma patients remain unreviewed, and youth asthma prescribing is 609 items per 1,000 aged 5–19 (England 1,488). Structured respiratory recalls could address unreviewed cohorts.
Cancer register and children's immunisation
Cancer prevalence reaches 5.0% (2,956 patients; England 3.8%). Childhood immunisations show 6-in-1 coverage at 12 months reaching 96.6% and MMR1 at age 5 reaching 95.0%. However, age-5 completion falls below the 95% target by 5 pp for MMR2 (90.0%) and by 11.7 pp for the 4-in-1 booster (83.3%). Structured call-and-recall could support second-dose coverage before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
Across NHS Surrey Heartlands ICB in 2022, 61.4% of cancers with a known stage were diagnosed at stage 1 or 2 (2,955 of 4,810 staged cases; England 55.3%), below the 75.0% national ambition by 2028, representing about 650 extra early-stage cases a year across the system. Cancers with a known stage accounted for 67.7% of registered cancers (4,810 of 7,106; England 67.0%). Early-stage share was 48.1% for bowel cancer (England 47.0%) and 33.2% for lung cancer (England 33.8%). These system figures describe regional staging rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For cancer waiting times in provisional July 2026, Royal Surrey NHS Foundation Trust achieved 84.5% on the 62-day referral to treatment standard (standard 85.0%), ahead of Frimley Health NHS Foundation Trust (81.8%), Ashford and St Peter's Hospitals NHS Foundation Trust (76.4%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). On the 28-day faster diagnosis standard, Royal Surrey reached 82.6% (England 79.3%; standard 75.0%). In July 2026 diagnostics at Royal Surrey, 0.0% waited 6+ weeks for Magnetic Resonance Imaging and 38.5% waited 6+ weeks for Urodynamics - Pressures & Flows.
| Pathways within standard (%) | Royal Surrey | Ashford and St Peter's | Frimley Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.62 | 85.53 | 87.95 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.43 | 94.21 | 92.89 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 84.48 | 76.38 | 81.84 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Royal Surrey | Ashford and St Peter's | Frimley Health | England |
|---|---|---|---|---|
| MRI | 0.00 | 0.09 | 12.85 | 21.40 |
| CT | 0.15 | 9.27 | 0.63 | 9.92 |
| Echocardiography | 1.55 | 0.97 | 3.35 | 28.48 |
| Colonoscopy | 0.00 | 49.61 | 22.84 | 30.83 |
| Gastroscopy | 0.00 | 56.74 | 7.43 | 29.02 |
| All 15 DM01 tests | 8.82 | 23.12 | 7.49 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In provisional June 2026 community services data, adults aged 65 and older accounted for 69.6% of contacts among Guildford borough residents (76,215 of 109,530 contacts). These borough-level contacts describe local community service activity rather than PCN-level delivery.
Practice variation and patient experience
Phone access varies by 43.9 percentage points across member practices
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Horsley Medical | 105 | 0.0 | 89.1% | 83.2% | 96.2% |
| Villages Medical | 104 | 0.0 | 80.0% | 85.2% | 96.0% |
| Sheresurgeryanddispensary | 95 | 0.0 | 79.7% | 68.4% | 95.0% |
| Austen Road | 106 | 0.0 | 86.4% | 72.4% | 94.7% |
| St. Luke's Surgery | 124 | 0.0 | 74.3% | 73.6% | 85.9% |
| Merrow Park | 117 | 0.0 | 45.1% | 80.4% | 68.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve tracked three-year trends trail England despite high baseline review achievement
Between 2023 and 2025, 12 of 25 tracked three-year trends trailed England. The widest lags were heart failure reviews (-0.7% vs England +8.7%), COPD reviews (-1.4% vs England +2.8%), and smoking cessation offers, which fell 3.1 pp (England +0.1 pp) to 93.2% (England 94.2%). Conversely, three-year gains outpaced England for diabetes statin prescribing without cardiovascular disease (+8.0% vs England +2.1%), QRISK ≥ 20% lipid therapy (+8.4% vs England +6.2%), and blood pressure control aged 80+ (+4.1% vs England +2.2%). Slower review growth could reflect high starting attainment, which clinical review audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Learning disability register
Smoking support (SMI)
Hypertension treated to target
Diabetes statin (no CVD)
QRISK statin treatment
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Guildford | Asset | PCN | Guildford |
|---|---|---|---|---|---|
| Care homes (catchment) | 25 (858 beds) | n/a | Schools (catchment) | 81 | n/a |
| Children's centres | 4 | 6 | Places of worship | 60 | 78 |
| Libraries | 3 | 3 | Homelessness support (VCS) | 1 | 1 |
| Day centres (VCS) | n/a | 2 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 12 | 14 | Primary academies | 10 | 19 |
| Special schools | 1 | no data |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
High-risk lipid therapy recall review
Lipid therapy lags England for QRISK ≥ 20% at 57.0% (England 63.6%, Guildford 57.3%, ICB 59.4%), CKD at 62.3% (England 70.3%), and diabetes with CVD at 81.2% (England 84.4%). For discussion: practices could run pharmacist-led recall and medicines reviews for QRISK ≥ 20% and CKD cohorts not on lipid-lowering therapy. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review recall
Asthma review coverage is 70.4% of 3,360 patients (England 65.7%, Guildford 67.8%; 3-year change +2.4% vs England +4.4%), leaving 995 (about 1,000) unreviewed. For discussion: the PCN could introduce a shared recall template, flexible clinic slots, and inhaler checks for unreviewed asthma patients. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register validation audit
Recorded learning disability prevalence is 0.3% (178 patients) against Guildford (0.4%), the ICB (0.5%) and England (0.6%), a benchmark gap range of +33 to +167 patients. For discussion: practices could audit diagnostic coding and cross-check registers with social-care and special-education lists where governance allows. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Frailty and anticipatory care review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Target inclusion health cohorts (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation intervention review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| System pathway review (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Primary care telephony access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · High-risk lipid therapy recall review (p12) | Hypertension register · Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register validation audit (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
